
Taysha Gene Therapies, Inc.: financial statements
Price
$3.72
November 20, 2026Market cap $1.2B
What Ploutos Investor adds for Taysha Gene Therapies
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
-20.5% a year over 2 years
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Revenue | $15M | $8.3M | $9.8M | -20.5% |
| Operating income | -$72M | -$91M | -$110M | |
| Net income | -$112M | -$89M | -$109M | |
| Earnings per share | -$0.96 | -$0.36 | -$0.34 | |
| Earnings per share, basic | -$0.96 | -$0.36 | -$0.34 | |
| Margins | ||||
| Operating margin | -468.8% | -1,097.6% | -1,130.6% | |
| Net margin | -722.1% | -1,071.6% | -1,115.3% | |
Financial statements
TSHA's revenue, profits and cash flows from 2022 to 2022, 1 more fiscal year
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 4 fiscal years.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
When the debt falls due
Dec 31, 2025Due within 2 years
$0
Total falling due
$50M
Total in the ladder $50M, from the annual report dated December 31, 2025. Principal of loans and bonds, without leases and interest. The filing
- 2026: –
- 2027: –
- 2028: –
- 2029: $12M
- 2030: $38M
- 2031 on: –
The ladder at each year end
| Year | 1 yr | 2 yrs | 3 yrs | 4 yrs | 5 yrs | Later |
|---|---|---|---|---|---|---|
| 2025 | – | – | – | $12M | $38M | – |
| 2024 | – | – | – | $19M | $21M | – |
| 2023 | – | – | – | $19M | $21M | – |
The ladder at each year end
When TSHA's debt fell due, as each annual report set it out, from 2021 to 2022, 2 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Leases
Dec 31, 2025Operating leases
$20M
Finance leases
$379.0K
- Average discount rate
- 8.6%
- Lease cost for the year
- $2.8M
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
Operating lease payments by year
Lease liability by year
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
21.0%
Effective rate
0.0%
The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Tax credits
+6.1 pts
Change in valuation allowance
-23.1 pts
Non-deductible expenses
-2.6 pts
Share-based compensation
-1.3 pts
Uncertain tax positions
-0.1 pts
Effective rate
0.0%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Effective tax rate by year
Effective tax rate by year
The tax rate TSHA paid on its profit, from 2020 to 2022, 3 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Taysha Gene Therapies's filings show?
These are Taysha Gene Therapies's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did TSHA have in 2025?
Taysha Gene Therapies had revenue of $9.8M and net income of -$109M in fiscal 2025, a net margin of -1,115.3%.
How much debt does TSHA have?
On December 31, 2025 Taysha Gene Therapies had total assets of $343M, debt of $50M and shareholders' equity of $247M.
How much free cash flow does TSHA have?
In fiscal 2025 Taysha Gene Therapies had cash from operations of -$93M and spent $738.0K on capital expenditure, leaving -$94M of free cash flow.
Where are the figures from?
From Taysha Gene Therapies, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.